Eli Lilly's Foundayo just cleared a key European Medicines Agency panel for obesity and type 2 diabetes, putting direct pressure on Novo Nordisk (CPSE:NOVO B) and its oral Wegovy pill in the obesity treatment market. Novo Nordisk's share price has moved to DKK259.6, with the stock down 21.39% on a year to date share price basis and the 1-year total shareholder return also down 20.63%, as investors weigh stronger GLP-1 competition, pricing pressure in the U.S., and softer Wegovy pill momentum against pipeline hopes such as CagriSema and early anti aging semaglutide data.
Главную мысль мы показываем публично. Создайте бесплатный аккаунт, чтобы читать статью полностью, сохранять ее, обсуждать и связывать с рынками и OSINT-контекстом.